Concomitant medications were used by 88% of subjects in the pancreatin group and 92% of subjects in the placebo group in the double-blind period, the most frequent being drugs for peptic ulcer and gastro-oesophageal reflux disease (38% and 50%, respectively), insulins and analogues (41% and 39%, respectively), and beta-blockers (22% and 23% respectively). This evidence concerns the gene INS and Peptic ulcer.